NASDAQ:COLL

Collegium Pharmaceutical Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy COLL

*Your capital is at risk

$31.06

+0.580 (+1.90%)

At Close: Jun 03, 2026

Collegium Pharmaceutical Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -64.76. In total, the insiders bought 860.21K and sold 468.05K COLL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-64.76
● Buy	860.21K shares
● Sell	468.05K shares
62% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Mar 03, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -64.76. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Nov 06, 2025 Sell	Common Stock S-Sale	Tupper Colleen EVP & Chief Financial Officer	C-Suite Officer	4 858 Value: $200.5K
Aug 29, 2025 Sell	Common Stock S-Sale	Smith Thomas B EVP And Chief Medical Officer	Officer	17 478 Value: $671.6K
Aug 29, 2025 Sell	Common Stock S-Sale	Smith Thomas B EVP And Chief Medical Officer	Officer	17 478 Value: $671.6K
Aug 18, 2025 Buy	Common Stock M-Exempt	Dreyer Scott EVP & Chief Commercial Officer	Officer	16 389 Value: $349.7K
Aug 18, 2025 Sell	Common Stock S-Sale	Dreyer Scott EVP & Chief Commercial Officer	Officer	16 389 Value: $626.2K
Aug 18, 2025 Buy	Stock Option (Right to Purchase) M-Exempt	Dreyer Scott EVP & Chief Commercial Officer	Officer	16 389 Value: $349.7K
Aug 18, 2025 Buy	Stock Option (Right to Purchase) M-Exempt	Dreyer Scott EVP & Chief Commercial Officer	Officer	16 389 Value: $349.7K
Aug 18, 2025 Sell	Common Stock S-Sale	Dreyer Scott EVP & Chief Commercial Officer	Officer	16 389 Value: $626.2K
Aug 18, 2025 Buy	Common Stock M-Exempt	Dreyer Scott EVP & Chief Commercial Officer	Officer	16 389 Value: $349.7K
Aug 15, 2025 Buy	Common Stock M-Exempt	Santini Gino Director	Director	15 000 Value: $201.8K
Aug 15, 2025 Sell	Common Stock S-Sale	Santini Gino Director	Director	5 405 Value: $201.0K
Aug 15, 2025 Buy	Stock Option (Right to Purchase) M-Exempt	Santini Gino Director	Director	15 000 Value: $201.8K
Aug 15, 2025 Buy	Stock Option (Right to Purchase) M-Exempt	Santini Gino Director	Director	15 000 Value: $201.8K
Aug 15, 2025 Sell	Common Stock S-Sale	Santini Gino Director	Director	5 405 Value: $201.0K
Aug 15, 2025 Buy	Common Stock M-Exempt	Santini Gino Director	Director	15 000 Value: $201.8K
Aug 13, 2025 Buy	Common Stock M-Exempt	Dreyer Scott EVP & Chief Commercial Officer	Officer	4 861 Value: $103.7K
Aug 13, 2025 Sell	Common Stock S-Sale	Dreyer Scott EVP & Chief Commercial Officer	Officer	4 861 Value: $184.9K
Aug 13, 2025 Buy	Stock Option (Right to Purchase) M-Exempt	Dreyer Scott EVP & Chief Commercial Officer	Officer	4 861 Value: $103.7K
Aug 13, 2025 Sell	Common Stock, par value $0.001 per share S-Sale	Rubric Capital Management Lp 10 Percent Owner	10% Owner	25 000 Value: $946.3K
Aug 13, 2025 Sell	Common Stock, par value $0.001 per share S-Sale	Rubric Capital Management Lp 10 Percent Owner	10% Owner	25 000 Value: $946.3K
Aug 13, 2025 Buy	Stock Option (Right to Purchase) M-Exempt	Dreyer Scott EVP & Chief Commercial Officer	Officer	4 861 Value: $103.7K
Aug 13, 2025 Sell	Common Stock S-Sale	Dreyer Scott EVP & Chief Commercial Officer	Officer	4 861 Value: $184.9K
Aug 13, 2025 Buy	Common Stock M-Exempt	Dreyer Scott EVP & Chief Commercial Officer	Officer	4 861 Value: $103.7K
Aug 08, 2025 Sell	Common Stock S-Sale	Freund John Gordon Director	Director	11 659 Value: $400.6K
Aug 08, 2025 Sell	Common Stock S-Sale	Freund John Gordon Director	Director	11 659 Value: $400.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT COLLEGIUM PHARMACEUTICAL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatm...

Read Full Profile Here